Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia. Design and Methods We studied 605 patients with essential thrombocythemia (follow-up 4596 person-years) with the aim of defining prognostic factors for thrombosis, myelofibrosis, and leukemia during follow-up. Results Sixty-six patients (11%) developed thrombosis with a 10-year risk of 14%. Age >60 years (p60 years (p=0.02) was significantly correlated with the development of leukemia. Cytotoxic treatment did not imply a higher risk of leukemia. At the time of the analysis, 64 of the 605 patients (10.6%) had died. The 10-year probability of survival was 88%, wit...
Essential thrombocythemia (ET) is a myeloproliferative neoplastic disease characterized by abnormal ...
This study investigates disease characteristics and clinical outcome in young patients (<40 years) w...
Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (...
Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this d...
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study...
To identify prognostic factors affecting thrombosis-free survival (TFS) and overall survival (OS), w...
The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing ess...
Myeloproliferative neoplasms include essential thrombocythemia (ET), polycythemia vera (PV), and pri...
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic even...
Myeloproliferative neoplasms include essential thrombocythemia (ET), polycythemia vera (PV), and pri...
Essential Thrombocythemia (ET) is currently classified as a Philadelphia negative myeloproliferative...
Essential thrombocythemia (ET) is a myeloproliferative neoplastic disease characterized by abnormal ...
This study investigates disease characteristics and clinical outcome in young patients (<40 years) w...
Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (...
Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this d...
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study...
To identify prognostic factors affecting thrombosis-free survival (TFS) and overall survival (OS), w...
The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing ess...
Myeloproliferative neoplasms include essential thrombocythemia (ET), polycythemia vera (PV), and pri...
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic even...
Myeloproliferative neoplasms include essential thrombocythemia (ET), polycythemia vera (PV), and pri...
Essential Thrombocythemia (ET) is currently classified as a Philadelphia negative myeloproliferative...
Essential thrombocythemia (ET) is a myeloproliferative neoplastic disease characterized by abnormal ...
This study investigates disease characteristics and clinical outcome in young patients (<40 years) w...
Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (...